Glaukos (GKOS) vs Smith & Nephew SNATS (SNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Glaukos (GKOS) has outperformed Smith & Nephew SNATS (SNN) over the past year, gaining 84.1% versus a loss of 25.0%. Over five years, GKOS leads with a +284.2% price change compared with -23.8% for SNN. Smith & Nephew SNATS is the larger company by market cap ($11.28 billion vs $9.51 billion), about 1.2 times the size, while Glaukos is growing revenue faster (+32.3% vs +6.1%).
On valuation, Smith & Nephew SNATS trades at a lower forward P/E (11.2x vs 308.1x for Glaukos). Smith & Nephew SNATS pays a dividend yielding 1.47%, while Glaukos does not currently pay one. Smith & Nephew SNATS converts more of its revenue into profit, with a net margin of 10.1% versus -37.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GKOS | SNN |
|---|---|---|
| Share price | $161.29 | $26.96 |
| Market cap | $9.51B | $11.28B |
| 1-day change | -6.32% | +0.26% |
| YTD return | +42.85% | -17.83% |
| 1-year return | +84.14% | -24.97% |
| 5-year return | +284.16% | -23.82% |
| P/E ratio (TTM) | — | 18.34 |
| Forward P/E | 308.06 | 11.18 |
| EPS (TTM) | $-3.26 | $1.47 |
| Dividend yield | 0.00% | 1.47% |
| Annual dividend | $0.00 | $0.397 |
| Revenue (latest FY) | $507.44M | $6.16B |
| Revenue growth (YoY) | +32.33% | +6.09% |
| Net income (latest FY) | $-187.69M | $625.00M |
| Gross margin | 55.72% | 68.01% |
| Operating margin | -39.33% | 12.88% |
| Net margin | -36.99% | 10.14% |
| 52-week high | $191.62 | $37.51 |
| 52-week low | $73.16 | $26.12 |
| Distance from 52-week high | -15.83% | -28.13% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +23.19% | +19.88% |
| Average volume | 831.71K | 1.65M |
| Shares outstanding | 58.98M | 418.52M |
| Employees | 1,094 | 17,000 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GKOS has outperformed SNN by 109.1 percentage points over the past year.
- Smith & Nephew SNATS offers a meaningfully higher dividend yield (1.47% vs 0.00%).
- Smith & Nephew SNATS is more profitable, keeping 10.1 cents of every revenue dollar as net income versus -37.0 cents for Glaukos.
- Glaukos grew revenue faster in its latest fiscal year (+32.33% vs +6.09%).
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Healthcare · Medical Devices · 1,094 employees
About Smith & Nephew SNATS
SNN stock →Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Healthcare · Medical Devices · 17,000 employees
GKOS vs SNN FAQ
Which is bigger, Glaukos or Smith & Nephew SNATS?
Smith & Nephew SNATS (SNN) is larger, with a market capitalization of $11.28B compared with $9.51B for Glaukos (GKOS).
Which stock has performed better over the past year, GKOS or SNN?
GKOS returned +84.14% over the past 12 months, compared with -24.97% for SNN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Glaukos or Smith & Nephew SNATS?
Smith & Nephew SNATS pays a dividend yielding 1.47%, while Glaukos does not currently pay a regular dividend.
Are Glaukos and Smith & Nephew SNATS in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.